---
schema_version: "secwatch.filing_event.v1"
accession: "0001411690-26-000027"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2026-05-13T20:03:04+00:00"
generated_at: "2026-05-13T22:18:41.940833+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bionano Q1 revenue $6.7M (+4% YoY); gross margin 49%; positive coding updates

## Summary
- Total revenue $6.7M (+4% vs $6.5M Q1 2025); consumables revenue $3.9M (+20%).
- Gross margin improved to 49% from 46% YoY; sold 8,178 nanochannel flow cells (+17%).
- Operating expenses cut 2% to $11.1M; adjusted op. expense +7% to $9.1M.
- New CPT code 81354 for OGM in constitutional genetics effective Jan 1, 2026, priced above microarray codes.
- Final CLFS shows 47% payment increase for CPT 81195 (OGM in hematologic malignancy) to $1,853.22.

## SEC filing metadata
- accession: 0001411690-26-000027
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2026-05-13T20:03:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000141169026000027/0001411690-26-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000141169026000027/bngo-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411690-26-000027
- JSON: https://secwatch.observer/filing/0001411690-26-000027.json
- Plain text: https://secwatch.observer/filing/0001411690-26-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.